Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL987525 | 0.86 | TAAR1 (0.71) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL29664514 | 0.86 | TAAR1 (0.57) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL28123545 | 0.86 | TAAR1 (0.57) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL2485767 | 0.86 | TAAR1 (0.57) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL2995202 | 0.86 | TAAR1 (0.45) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL9959103 | 0.85 | TAAR1 (0.44) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL11854830 | 0.84 | TAAR1 (0.51) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL180328 | 0.83 | TAAR1 (0.43) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL108087 | 0.82 | TAAR1 (0.77) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 | |
| Safrazine SCHEMBL437129 | 0.82 | TAAR1 (0.57) | TAAR1SLC6A4SLC6A2SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
| US-10946000-B2 | Method for treating cancer with combination therapy | REDHILL BIOPHARMA LTD. (IL) | 2021-03-16 | — | — | US | disclosed |
| US-20200231596-A1 | MATTER OF COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF FL118 PLATFORM POSITIONS 7 AND 9-DERIVED ANALOGUES FOR TREATMENT OF HUMAN DISEASE | CANGET BIOTEKPHARMA | 2020-07-23 | — | — | US | disclosed |
| US-20200223826-A1 | Glucose-6-Phosphate Dehydrogenase (G6PD)-Modulating Agents And Methods Of Treating G6PD Deficiency | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2020-07-16 | — | — | US | disclosed |
| US-9856246-B2 | TRPM8 antagonists | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2018-01-02 | — | — | US | disclosed |
| US-9844540-B2 | Combination therapies for treating cancer | REDHILL BIOPHARMA LTD. (IL) | 2017-12-19 | — | — | US | disclosed |
| US-20170129881-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-05-11 | — | — | US | disclosed |
| US-20170095460-A1 | COMBINATION THERAPIES FOR TREATING CANCER | REDHILL BIOPHARMA LTD. (IL) | 2017-04-06 | — | — | US | disclosed |
| US-9585875-B2 | TRPM8 antagonists | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-03-07 | — | — | US | disclosed |
| US-20140371276-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2014-12-18 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080161288-A1 | COMPOUNDS | PFIZER INC. | 2008-07-03 | — | — | US | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| US-7342026-B2 | Substituted quinolines for the treatment of protozoa and retrovirus co-infections | INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (FR) | 2008-03-11 | — | — | US | disclosed |
| WO-2005021584-A2 | NOVEL PEPTIDOMIMETIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | BET1, BRD4, BRD3 | TAAR1 816/4885SLC6A4 4500/4885SLC6A2 3665/4885 |
| US-20170129881-A1 | TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM5 | TAAR1 376/4885SLC6A4 791/4885SLC6A2 1224/4885 |
| US-20200231596-A1 | MATTER OF COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF FL118 PLATFORM POSITIONS 7 AND 9-DERIVED ANALOGUES FOR TREATMENT OF HUMAN DISEASE | TP53, BRCA1, MET | TAAR1 2545/4885SLC6A4 4557/4885SLC6A2 4691/4885 |
| US-20140371276-A1 | TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPV1 | TAAR1 401/4885SLC6A4 816/4885SLC6A2 1079/4885 |
| US-20200223826-A1 | Glucose-6-Phosphate Dehydrogenase (G6PD)-Modulating Agents And Methods Of Treating G6PD Deficiency | G6PD, DPYD, G6PC1 | TAAR1 4794/4885SLC6A4 3617/4885SLC6A2 3101/4885 |
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | TAAR1 4274/4885SLC6A4 4539/4885SLC6A2 4169/4885 |
| US-10946000-B2 | Method for treating cancer with combination therapy | TPMT, KRAS, SDHA | TAAR1 2003/4885SLC6A4 571/4885SLC6A2 201/4885 |
| US-20080161288-A1 | COMPOUNDS | ADRB2, ADRB1, ADRA2C | TAAR1 97/4885SLC6A4 396/4885SLC6A2 19/4885 |
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | AXL, FLT3, TYMP | TAAR1 1464/4885SLC6A4 4212/4885SLC6A2 4376/4885 |
| US-20170095460-A1 | COMBINATION THERAPIES FOR TREATING CANCER | KRAS, ACE, TPMT | TAAR1 2780/4885SLC6A4 615/4885SLC6A2 323/4885 |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | TAAR1 305/4885SLC6A4 441/4885SLC6A2 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.